TLDR Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.
This systematic review evaluates the use of dupilumab, a monoclonal antibody, in treating various inflammatory skin diseases beyond its initial approval for atopic dermatitis. Dupilumab has shown effectiveness in conditions such as alopecia areata, chronic spontaneous urticaria, and Netherton syndrome, among others. Clinical trials, including the phase 3 LIBERTY-PN PRIME and PRIME2, demonstrated significant improvements in symptoms for 153 patients with prurigo nodularis. Dupilumab's safety profile is favorable, with mild adverse events like nasopharyngitis. The review underscores dupilumab's potential for broader application in dermatology, though its efficacy varies among different conditions and individual cases.
3 citations
,
December 2021 in “Dermatology reports” Dupilumab can improve both atopic dermatitis and alopecia universalis.
2 citations
,
September 2021 in “JAAD case reports” Dupilumab helped a woman with severe hair loss regrow her hair quickly and maintain it for six months after stopping treatment.
7 citations
,
July 2021 in “JAAD case reports” Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.
19 citations
,
January 2021 in “Journal of the American Academy of Dermatology” Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.
29 citations
,
July 2019 in “Dermatologic Therapy” Dupilumab can both heal and cause hair loss.
19 citations
,
January 2019 in “JAAD case reports” A medication for skin rash also unexpectedly treated hair loss in a patient.
33 citations
,
January 2019 in “Acta Dermato Venereologica” Dupilumab may help regrow hair in people with atopic dermatitis.
50 citations
,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
January 2022 in “Dermatology Review” Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.
Dupilumab may cause hair loss, so patients should be monitored.
January 2020 in “Journal of The European Academy of Dermatology and Venereology” In 2019, dermatology and venereology improved skin cancer imaging, advanced in treating skin conditions like psoriasis, and explored the skin microbiome's role in diseases.
July 2018 in “Elsevier eBooks” Up to half of people experience itchy scalp, often due to skin conditions like seborrheic dermatitis or psoriasis, and treatments vary based on the specific cause.
